C
Cristina Saro
Researcher at Spanish National Research Council
Publications - 49
Citations - 948
Cristina Saro is an academic researcher from Spanish National Research Council. The author has contributed to research in topics: Rumen & Hay. The author has an hindex of 13, co-authored 49 publications receiving 795 citations. Previous affiliations of Cristina Saro include Institut national de la recherche agronomique & University of Auvergne.
Papers
More filters
Journal ArticleDOI
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
María José Casanova,María Chaparro,E. Domènech,M. Barreiro-de Acosta,Fernando Bermejo,Eva Iglesias,Fernando Gomollón,Luis Rodrigo,Xavier Calvet,Maria Esteve,Esther Garcia-Planella,Santiago García-López,Carlos Taxonera,Mari M. Calvo,Manuel López,Daniel Ginard,María Gómez-García,Elena Garrido,J L Pérez-Calle,Belén Beltrán,M Piqueras,Cristina Saro,B. Botella,Carmen Duenas,Ángel Ponferrada,Míriam Mañosa,Valle García-Sánchez,J. Maté,Javier P. Gisbert +28 more
TL;DR: The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn.
Journal ArticleDOI
Efficacy and safety of short‐term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open‐label, multicentre trial
Joaquín Hinojosa,Fernando Gomollón,S. A. Garcia,Guillermo Bastida,José Luis Cabriada,Cristina Saro,D Ceballos,M. Penate,Miquel A. Gassull +8 more
TL;DR: The use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease and led to new treatments for the disease.
Journal ArticleDOI
Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab.
Carlos Taxonera,Jesús Estellés,Ignacio Fernández-Blanco,Olga Merino,Ignacio Marín-Jiménez,M. Barreiro-de Acosta,Cristina Saro,Valle García-Sánchez,Elena Gento,Guillermo Bastida,Javier P. Gisbert,Isabel Vera,Pilar Martínez-Montiel,S. Garcia-Morán,María Chaparro Sánchez,J.L. Mendoza +15 more
TL;DR: Aliment Pharmacol Ther 2011; 33: 340–348.
Journal ArticleDOI
Comparison of fermentation of diets of variable composition and microbial populations in the rumen of sheep and Rusitec fermenters. II. Protozoa population and diversity of bacterial communities.
M. E. Martínez,M. E. Martínez,M. J. Ranilla,M. J. Ranilla,María L. Tejido,María L. Tejido,Cristina Saro,Cristina Saro,María Dolores Carro,María Dolores Carro +9 more
TL;DR: Assessment of how closely fermenters can mimic the differences between diets found in vivo indicates that under the conditions of the present study, protozoa population in Rusitec fermenters was not representative of that in the rumen of sheep fed the same diets.
Journal ArticleDOI
Long-term durability of response to adalimumab in Crohn's disease
María Chaparro,Julián Panés,Valle Garcia,Olga Merino,Pilar Nos,E. Domènech,Mireia Peñalva,Esther Garcia-Planella,Maria Esteve,Joaquín Hinojosa,Montserrat Andreu,Fernando Muñoz,Ana Gutiérrez,Juan Luis Mendoza,Jesus Barrio,M Barreiro-de,Isabel Vera,Pere Vilar,José Luis Cabriada,Miguel Montoro,Xavier Aldeguer,Cristina Saro,Javier P. Gisbert +22 more
TL;DR: A relevant proportion of CD patients on long‐term adalimumab lost response and the risk of loss of response was higher (more than 2‐fold) in anti‐TNF‐experienced patients than in anti-T NF‐naïve patients (22% vs. 8% per patient‐year of treatment).